Form 8-K - Current report:
SEC Accession No. 0001193125-22-148643
Filing Date
2022-05-12
Accepted
2022-05-12 16:10:57
Documents
12
Period of Report
2022-05-10
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d309018d8k.htm   iXBRL 8-K 31741
  Complete submission text file 0001193125-22-148643.txt   154075

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA lrmr-20220510.xsd EX-101.SCH 2864
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE lrmr-20220510_lab.xml EX-101.LAB 17996
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lrmr-20220510_pre.xml EX-101.PRE 11267
6 EXTRACTED XBRL INSTANCE DOCUMENT d309018d8k_htm.xml XML 3360
Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Filer) CIK: 0001374690 (see all company filings)

EIN.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36510 | Film No.: 22917902
SIC: 2834 Pharmaceutical Preparations